Decipher Biosciences, Inc.
🏢 View company profile →7Patents
7Active
7Granted
45Portfolio score
Filing activity: Dec 13, 2012 → May 11, 2018
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10513737B2 | Cancer diagnostics using non-coding transcripts | Emerging Cross-Sectional Technologies | 6 | Active |
| US10865452B2 | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer | Emerging Cross-Sectional Technologies | 6 | Active |
| US11078542B2 | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness | Physics | 2 | Active |
| US11035005B2 | Cancer diagnostics using biomarkers | Chemistry; Metallurgy | 2 | Active |
| US11208697B2 | Molecular subtyping, prognosis, and treatment of bladder cancer | Chemistry; Metallurgy | 1 | Active |
| US11873532B2 | Subtyping prostate cancer to predict response to hormone therapy | Physics | 0 | Active |
| US11414708B2 | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.